Raymond James Keeps Bullish View on Biotech G1 After 43% Slide

(Bloomberg) -- Raymond James is keeping its strong buy rating on G1 Therapeutics Inc. after the stock plunged 43 percent Thursday on what analyst Dane Leone called “misinterpretations” of clinical ...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.